MaaT Pharma publishes half-year 2024 results and provides business update

Regulatory news:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and leader in the development of microbiome ecosystem therapies^TM (MET), a company dedicated to improving the survival of cancer patients through immunomodulation, today announced its half-year results for the six-month period ended June 30, 2024 and provided a business overview.

“Building on the positive data for MaaT013 presented at the EBMT Congress in April 2024 and the success of our recent fundraising, we have dedicated the first half of 2024 to recruiting and preparing for the topline results of our ongoing Phase 3 clinical trial for MaaT013. This trial is designed to address the urgent unmet medical need of patients with acute graft-versus-host disease who are refractory to current treatments. Currently, there is an 85% mortality rate within one year for patients requiring third-line treatment options. In addition, by extending our cash runway by another quarter, we are well positioned to achieve our near-term milestones,” explained Siân Crouzet, Chief Financial Officer of MaaT Pharma.